235 related articles for article (PubMed ID: 20943209)
1. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
[TBL] [Abstract][Full Text] [Related]
2. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.
Jackson LA; Jacobson RM; Reisinger KS; Anemona A; Danzig LE; Dull PM
Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
[TBL] [Abstract][Full Text] [Related]
5. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
6. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
7. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.
Chang LJ; Hedrick J; Christensen S; Pan J; Jordanov E; Dhingra MS
Vaccine; 2020 Apr; 38(19):3560-3569. PubMed ID: 32209248
[TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
[TBL] [Abstract][Full Text] [Related]
9. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
Johnston W; Essink B; Kirstein J; Forleo-Neto E; Percell S; Han L; Keshavan P; Smolenov I
Pediatr Infect Dis J; 2016 Jan; 35(1):e19-27. PubMed ID: 26398741
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
Stamboulian D; Lopardo G; Lopez P; Cortes-Barbosa C; Valencia A; Bedell L; Karsten A; Dull PM
Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P
Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
Bona G; Castiglia P; Zoppi G; de Martino M; Tasciotti A; D'Agostino D; Han L; Smolenov I
Vaccine; 2016 Jun; 34(29):3363-70. PubMed ID: 27181507
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Zambrano B; Peterson J; Deseda C; Julien K; Spiegel CA; Seyler C; Simon M; Hoki R; Anderson M; Brabec B; Áñez G; Shi J; Pan J; Hagenbach A; Von Barbier D; Varghese K; Jordanov E; Dhingra MS
Pediatr Res; 2023 Sep; 94(3):1035-1043. PubMed ID: 36899125
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM
Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: results of an open label study.
Huang LM; Chiu NC; Yeh SJ; Bhusal C; Arora AK
Vaccine; 2014 Sep; 32(40):5177-84. PubMed ID: 25075804
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]